JP2023508938A5 - - Google Patents

Info

Publication number
JP2023508938A5
JP2023508938A5 JP2022538731A JP2022538731A JP2023508938A5 JP 2023508938 A5 JP2023508938 A5 JP 2023508938A5 JP 2022538731 A JP2022538731 A JP 2022538731A JP 2022538731 A JP2022538731 A JP 2022538731A JP 2023508938 A5 JP2023508938 A5 JP 2023508938A5
Authority
JP
Japan
Prior art keywords
compound according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538731A
Other languages
English (en)
Japanese (ja)
Other versions
JP7736275B2 (ja
JP2023508938A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067074 external-priority patent/WO2021134045A1/en
Publication of JP2023508938A publication Critical patent/JP2023508938A/ja
Publication of JP2023508938A5 publication Critical patent/JP2023508938A5/ja
Priority to JP2025136672A priority Critical patent/JP2025186252A/ja
Application granted granted Critical
Publication of JP7736275B2 publication Critical patent/JP7736275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538731A 2019-12-26 2020-12-26 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 Active JP7736275B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136672A JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953860P 2019-12-26 2019-12-26
US62/953,860 2019-12-26
PCT/US2020/067074 WO2021134045A1 (en) 2019-12-26 2020-12-26 Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136672A Division JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2023508938A JP2023508938A (ja) 2023-03-06
JP2023508938A5 true JP2023508938A5 (cg-RX-API-DMAC7.html) 2024-01-25
JP7736275B2 JP7736275B2 (ja) 2025-09-09

Family

ID=76575158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538731A Active JP7736275B2 (ja) 2019-12-26 2020-12-26 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
JP2025136672A Pending JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136672A Pending JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Country Status (7)

Country Link
US (1) US20230303710A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081219A4 (cg-RX-API-DMAC7.html)
JP (2) JP7736275B2 (cg-RX-API-DMAC7.html)
CN (1) CN115335052A (cg-RX-API-DMAC7.html)
AU (1) AU2020412805A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165475A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021134045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4081215B1 (en) * 2019-12-26 2026-05-20 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
WO2023278778A1 (en) * 2021-06-30 2023-01-05 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
EP4436579A4 (en) * 2021-11-22 2025-10-22 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM IN CONJUNCTION WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIA ACTIONS
WO2025202415A1 (en) * 2024-03-28 2025-10-02 Institut National de la Santé et de la Recherche Médicale Dhodh inhibitors for use in the chronopharmacoligical treatment and prevention of obesity and obesity-related metabolic disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
JP6055404B2 (ja) * 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
EP3344243B1 (en) * 2015-09-01 2020-12-09 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
MX2018008169A (es) * 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
US10478497B2 (en) * 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
EP3661557B1 (en) * 2017-07-31 2025-09-03 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
CA3103557A1 (en) * 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
EP4081215B1 (en) * 2019-12-26 2026-05-20 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
EP4081520A1 (en) * 2019-12-26 2022-11-02 Ohio State Innovation Foundation Compositions for use in the inhibition of dihydroorotate dehydrogenase
EP4081512A1 (en) * 2019-12-26 2022-11-02 Ohio State Innovation Foundation Compositions for use for the inhibition of dihydroorotate dehydrogenase

Similar Documents

Publication Publication Date Title
JP2023164986A5 (cg-RX-API-DMAC7.html)
JP2021184963A5 (cg-RX-API-DMAC7.html)
JP2023171775A5 (cg-RX-API-DMAC7.html)
JP2023166402A5 (cg-RX-API-DMAC7.html)
JP2023526975A5 (cg-RX-API-DMAC7.html)
JP2022541332A5 (cg-RX-API-DMAC7.html)
JP2023514727A5 (cg-RX-API-DMAC7.html)
JP2023113681A5 (cg-RX-API-DMAC7.html)
JP2022538215A5 (cg-RX-API-DMAC7.html)
JPWO2020148954A5 (cg-RX-API-DMAC7.html)
JP2023552816A5 (cg-RX-API-DMAC7.html)
JP2023041070A5 (cg-RX-API-DMAC7.html)
JP2023181322A5 (cg-RX-API-DMAC7.html)
JP2022116141A5 (cg-RX-API-DMAC7.html)
JP2022544380A5 (cg-RX-API-DMAC7.html)
JPWO2022202973A5 (cg-RX-API-DMAC7.html)
JP2021129286A5 (cg-RX-API-DMAC7.html)
JP2020079331A5 (cg-RX-API-DMAC7.html)
JP2024507827A5 (cg-RX-API-DMAC7.html)
JP2022507958A5 (cg-RX-API-DMAC7.html)
JP2023156274A5 (cg-RX-API-DMAC7.html)
JP2023093656A5 (cg-RX-API-DMAC7.html)
JP2022518056A5 (cg-RX-API-DMAC7.html)
JP2023182736A5 (cg-RX-API-DMAC7.html)
JP2022505925A5 (cg-RX-API-DMAC7.html)